Haematopoietic cell transplantation (HCT) involves the treatment of recipients with irradiation and/or chemo therapy followed by the infusion of cells containing haematopoietic stem and progenitor cells with or without immune cells, including T cells, B cells and natural killer (NK) cells. These haematopoietic cells can be obtained from bone marrow, cytokine-mobilized peripheral blood or umbilical cord blood (UCB). HCT was originally used to restore depleted haematopoietic cell populations in patients receiving high doses of irradiation and/or chemo therapy to treat haematological malignancies such as leukaemias. Radiotherapies and chemotherapies cause failure of haematopoiesis, so the engrafted donor haemato poietic stem cells (HSCs) reconstitute the haemato poietic system. The inclusion of mature immune cells in the donor graft has a major impact on the outcome of HCT. Clinical and laboratory studies have clearly shown that allogeneic HCT can mediate graftversustumour (GVT) effects in which donorderived immune cells attack the host tumours. However, this beneficial effect is largely T cellmediated and is offset by the associated complica tion of graft-versus-host disease (GVHD), in which normal host tissues are attacked by donor T cells. In addition, the high doses of irradiation and/or chemotherapy that are used for conditioning the recipients induce severe toxic ity, limiting the use of HCT to younger patients. GVHD is potentiated by conditioninginduced inflammation, which enhances the effector functions of donor T cells and facilitates the infiltration of activated donor T cells to the GVHD target tissues. In the past 20 years, HCT has been increasingly performed using reduced intensity or non-myeloablative conditioning regimens. Use of the term 'nonmyeloablative conditioning' in this article denotes conditioning that leaves sufficient recipient haemato poiesis in place to avoid lethal failure of the bone marrow in the absence of a replacement haematopoietic graft.
HCT can be categorized into autologous and alloge neic on the basis of the source of haematopoietic cells. Advances in HCT have enabled the use of more diverse sources of donor haematopoietic cells and, furthermore, extended its use as a treatment for a broader range of diseases (TABLE 1) . The number of HCT procedures performed worldwide is estimated to be 55,000-60,000 each year 1 , and most procedures are performed for the treatment of haematological malignancies. In this Review, we summarize advances in HCT, focusing on the issues that are likely to have the greatest future impact. We describe the advances that have been made in using alternative donors, in improving conditioning regimes and in enhancing immune reconstitution fol lowing HCT. In addition, we discuss the use of HCT as a tumour immunotherapy and, conversely, its potential to promote immune tolerance in the setting of organ transplantation or autoimmune disease. GVHD is not the focus of our Review, as it is covered in detail elsewhere in this issue 2 .
Alternative donors for HCT HLAmatched siblings, when available, are usually the firstchoice donors for HCT. When such a donor is not available, an HLAmatched unrelated donor may be sought. Despite the rapid expansion of donor regis tries over the past 20 years, the availability of unrelated donors is limited, especially for patients with uncom mon HLA genotypes
. If an appropriate unrelated donor cannot be found, alternative donors, including HLAmismatched unrelated donors, UCB and related haploidentical donors may be considered (FIG. 1) . UCB transplantation is associated with a decreased incidence of GVHD compared to bone marrow trans plantation, even in the presence of a greater degree of HLA mismatching 3, 4 . The mechanisms for this
Graft-versus-host disease (GVHD) . A pathological process mediated by host alloantigenactivated donor T cells attacking the normal tissues (mainly skin, gut and liver) of the host.
Non-myeloablative conditioning
Also known as reduced-intensity conditioning.
A less-intensive conditioning protocol that allows the engraftment of donor cells without ablating the host's haematopoietic system. Haematopoietic recovery occurs without engraftment of infused haematopoietic cells.
Autologous
In autologous transplantation, the infused haematopoietic cells are from the patients themselves.
reduction still remain largely unclear. The immaturity of neonatal T cells may be partially responsible, as CD4 + T cells from UCB showed defective activation and dif ferentiation in response to alloantigen stimulation 5 . In addition, concentrations of regulatory T (T Reg ) cells are higher in UCB than in adult blood 6, 7 . Moreover, den dritic cells from UCB demonstrated a more immature phenotype characterized by lower expression of MHC class II and costimulatory molecules. They are less able to promote T helper 1 (T H 1) cell differentiation and instead induce the generation of T Reg cells 8, 9 . These prop erties of the T cell and antigenpresenting cell (APC) compartments may contribute to the lower incidence of GVHD following UCB transplantation.
However, as the number of CD34 + cells from one unit of UCB is about onetenth of that in a bone marrow graft and 1/20-1/30 of that in a cytokinemobilized peripheral blood graft, the limited number of stem cells present in a UCB unit is associated with decreased engraftment and delayed immune reconstitution, especially in adult patients, thus limiting the success of UCB transplanta tion. This problem may be solved by using UCB from two different donors 10 , which can preserve GVT effects and enhance immune reconstitution 11, 12 . Other approaches to overcoming the limitation of low stem cell content have been investigated. One is to expand the stem cells ex vivo for transplantation. A recent study showed that infusion of ex vivoexpanded stem cells from one unit of cord blood together with another unit of unexpanded cord blood resulted in better engraftment and faster haemato poietic recovery than using two units of unexpanded cord blood alone 13 . The use of mesenchymal stem cells (MSCs) in the expansion system may enhance the efficacy of expan sion of UCBderived HSCs 14 . Despite evidence of benefi cial effects in vitro, cotransplantation of MSCs did not enhance engraftment of UCB 15, 16 . As studies have dem onstrated that injection of haematopoietic cells directly into bone marrow can improve the homing of haemato poietic cells, leading to faster haematopoietic recovery 17, 18 , this approach has recently been used to overcome the problem of low numbers of HSCs in UCB transplanta tion. When UCB grafts were injected directly into bone, high rates of engraftment and enhanced haematopoietic recovery with low rates of GVHD were reported 19, 20 . It is as yet unknown how this approach may affect immune reconstitution and GVT effects after UCB transplantation. 
Box 1 | Role of HLA matching in allogeneic HCT
HLA matching has typically been required in allogeneic haematopoietic cell transplantation (HCT), as HLA mismatching is associated with increased rejection rates, increased and more severe graft-versus-host disease (GVHD) and delayed immune reconstitution if graft T cell depletion is used to prevent GVHD. However, only 30% of patients have a suitable HLA-matched or one antigen-mismatched related donor. In this setting, significant GVHD still occurs in 30-50% of recipients despite the use of immunoprophylaxis. In this case, mismatched minor histocompatibility antigens expressed by HCT recipients are the targets of donor T cells. Minor histocompatibility antigens are immunogenic peptides derived from polymorphic self-proteins and are presented in the context of HLA. Donors for patients without matched related donors may be identified by searching registries for an HLA-matched unrelated donor. The chance of identifying such a donor depends on the patient's specific HLA alleles and ethnicity. It is easier to find a donor for a recipient with common HLA alleles than for a recipient with uncommon HLA alleles. As HLA matching is more likely to be achieved within the same ethnic group, patients in minority groups have greater difficulty finding HLA-matched unrelated donors. Although an ideal donor carries HLA alleles matched to those of a recipient at five HLA loci, including HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1, evidence suggests the existence of permissive loci whose mismatching is acceptable. For example, one study suggested that disparity at HLA-DQB1 in the presence of one or more mismatches at other loci was not associated with additional adverse effects 141 (advances in this field are reviewed in REF. 142 ). By contrast, studies have also suggested that certain HLA mismatches are associated with more severe adverse effects, such as GVHD 143 . T cell depletion may be performed to prevent graft-versus-host disease (GVHD), and/or donor-derived ex vivo-expanded mesenchymal stem cells may be added to the grafts to enhance engraftment and/or to prevent GVHD. b | Although a single unit of umbilical cord blood (UCB) graft can be used for haematopoietic cell transplantation (HCT), the limited number of haematopoietic stem cells (HSCs) is often associated with delayed engraftment and immune reconstitution. Engraftment can be enhanced by the addition of a second unit of UCB, or by the addition of ex vivo-expanded HSCs from another unit of UCB or from a haploidentical adult haematopoietic donor graft. In addition, recent studies have shown that grafts con sisting of one unit of UCB and haploidentical haemato poietic cells can lead to enhancement of engraftment and haematopoietic reconstitution [21] [22] [23] (FIG. 1b) .
For most patients, a haploidentical parent, sibling, child, aunt, uncle or other close relative can be identified. However, HLA disparities are associated with increased GVHD, graft rejection and poor immune reconstitution. be enriched by positive selection, also resulting in donor T cell depletion. The number of CD34 + cells in the donor graft is an important factor in determining the suc cess of the engraftment, especially when reduced intensity conditioning is used 24 . Alternatively, HSC enrichment and T cell depletion to prevent GVHD can be achieved by depleting T cells and B cells using antiCD3 and antiCD19 microbeads 25, 26 . This approach can preserve HSCs within the CD34 -cell population and other cell types that may facilitate the engraftment of donor grafts. Studies have shown that rapid engraftment of donor grafts can be achieved with this approach, even for grafts containing low numbers of CD34 + cells 25, 26 . NK cells have been shown to have a role in GVT effects in patients receiving myeloablative conditioning and haploidentical CD34 + cells. In haploidentical trans plant recipients with acute myeloid leukaemia, the use of donors whose NK cells expressed killer-cell immunoglobulin-like receptors (KIRs) that did not recognize (and could therefore not be inhibited by) the patients' MHC class I molecules was associated with markedly decreased relapse rates and improved survival rates 27, 28 . In mice, donorderived NK cells that were hostreactive (owing to missing inhibitory MHC class I ligands) inhibited GVHD by killing the host APCs required to initiate GVHD, but mediated GVT effects by directly killing the tumour cells 27 . For patients receiving T cellreplete haploidentical grafts, potent immunosuppressants must be adminis tered to prevent GVHD. These immunosuppressants may impair immune reconstitution and GVT effects. Recent studies showed that posttransplant administra tion of cyclophosphamide can help to prevent both GVHD and graft rejection (discussed below). For both UCB and haploidentical transplants, clinical outcomes can be fur ther optimized by selecting donors who encounter non inherited maternal (for the donor) HLA antigens in the recipients 29, 30 . It is unclear what mechanisms are respon sible for the phenomenon of hyporesponsiveness to non inherited maternal antigens, which has been described in human organ transplant recipients and in animal models. Recent studies in an animal model demonstrate that tolerance to noninherited maternal alloantigens was associated with partial deletion of the alloantigenspecific T cells and a T H 2polarized cytokine production profile, and it might involve CD4 + CD25
+ T Reg cells 31 . MSCs may also have utility in haploidentical transplantation. When cotransplanted with T celldepleted haplo identical grafts, ex vivoexpanded donorderived MSCs hastened lymphoid recovery in paediatric patients 32 . MSCs can suppress alloresponses in vitro 33 and may have the abil ity to suppress refractory GVHD [34] [35] [36] , regardless of their origin 34 . Thus, MSCs have several potential advantages that warrant further investigation in haploidentical HCT (FIG. 1a) . In addition, animal studies have shown that cotransplantation of donorderived T Reg cells with the graft leads to suppression of GVHD in a partially interleukin10 (IL10)dependent manner 37 . Thus, another promising approach involves the titration of donorderived T Reg cells with limited numbers of con ventional T cells in heavily conditioned haploidentical CD34 + cell transplant recipients 38 .
Reduced intensity conditioning Originally, myeloablative conditioning was used to max imize the killing of leukaemia cells before HCT, which was used as a rescue therapy for the haemato poietic destruction caused by the cancer therapy. However, the toxicity of myeloablative conditioning itself causes morbidity and mortality, and this treatment is con sidered to be too toxic for use in older patients or in patients who have active disease, have failed multiple or combined treatments, or have organ damage. The use of reduced intensity conditioning enables these patients to undergo HCT. Increased intensity of conditioning may also be associated with increased GVHD risk owing to increased inflammation and disruption of mucosal bar riers, allowing entry of proinflammatory microorgan isms into the underlying recipient tissues 39 . Following the realization that HCT also conferred immunothera peutic benefits in addition to providing haematopoietic rescue, reduced intensity conditioning regimens began to be explored, making HCT available for older patients. GVHD has not been markedly reduced by this approach, perhaps owing in part to the increased susceptibility of older patients to this complication. Tumour control may be achieved by GVT effects of donor T cells contained in the initial donor grafts or by T cells administered in donor leukocyte infusions (DLIs). Most reduced inten sity conditioning regimens include chemotherapeutic drugs, such as fludarabine, busulphan or cyclophospha mide, and/or a low dose of total body irradiation (TBI), and some include antibodies for T cell depletion, such as rabbit anti-thymocyte globulin (ATG) or antiCD52 (Campath). Reduced intensity conditioning protocols have been evaluated in haploidentical [40] [41] [42] and UCB transplantation 43 .
On the basis of studies in mice, which showed that enrichment of host natural killer T (NKT) cells induces an IL4dependent expansion of donor T Reg cells, the Stanford group developed a fractionated total lymphoid irradiation and ATGmediated T cell depletion protocol in order to reduce the incidence of GVHD 44 (TABLE 2) . In the mouse model, this condition ing regimen led to the enrichment of host NKT cells in the lymphoid tissues 45 and resulted in suppression of GVHD in association with T H 2type polarization of donor T cells 46 . Clinical trials in patients with haemato logical malignancies showed that the Stanford protocol was associated with a very low incidence of GVHD in HLAidentical allogeneic HCT, with apparently preserved GVT effects 47, 48 . Enrichment of NKT cells and increased numbers of donor IL4producing T cells were detected 47, 48 , suggesting similar mechanisms of GVHD suppression in humans and mice. It remains to be deter mined whether this approach can reduce GVHD in the HLAmismatched HCT setting.
Nonmyeloablative regimens developed at Massachusetts General Hospital (MGH) used cyclo phosphamide, thymic irradiation and T cell depletion (mediated by ATG 49 or CD2specific antibodies 42, 50 ) to achieve initial mixed chimerism from HLAidentical 49 or haploidentical donors 42, 50 , respectively. The inten tion of these protocols has been to use delayed DLI to r E V i E W S 406 | JUNE 2012 | VOLUME 12 www.nature.com/reviews/immunol r E V i E W S
Photodynamic purging
Refers to the process of deleting cells by introducing light-sensitive chemicals into the target cells, followed by exposure of these cells to light so that the chemicals cause the death of the target cells.
achieve maximal GVT effects while minimizing GVHD, as suggested by studies in mice (see below). The desired outcomes have been variably achieved in these trials, but additional manoeuvres are likely to be needed to better control the risk of GVHD from DLI 49 . Cyclophosphamide induces the death of activated T cells, and a regimen that includes both pretransplant and posttransplant cyclophosphamide has been evalu ated in clinical trials at Johns Hopkins University and at the Fred Hutchinson Cancer Research Center 51, 52 . Because both recipient T cells and donor T cells in the graft can be activated by alloantigens posttransplantation, these are exposed to cyclophosphamide and depleted, diminishing the risks of graft rejection and GVHD. These studies have achieved encouraging engraftment rates with acceptable rates of acute and chronic GVHD, but the impact of this protocol on GVT effects needs further study.
The protocols described above are associated with reduced GVHD while enabling the engraftment of allo geneic donor cells. The use of reduced intensity condi tioning has already enhanced the clinical application of HCT.
Enhancing immune reconstitution HCT can be associated with prolonged immunodefi ciency posttransplantation, especially after extensive treatment for underlying malignancies and the use of T celldepleted grafts. Considerable time (about 1-2 years) is needed for the complete regeneration of the T cell and B cell compartments, especially when the thymus has lost most of its function owing to age or prior therapies. GVHD and the immuno suppressive drugs used for its prevention can also severely delay immune reconstitution. During this time, patients are subject to opportunistic infections, which in many cases are fatal. Thus, effective approaches to hastening immune reconstitution following transplantation are needed. Several strategies for achieving this have been under active investigation, as we discuss in the following section (FIG. 2) .
Infusion of allodepleted donor T cells.
Allodepletion refers to the specific removal of antirecipient allo reactive T cells from the donor graft. Transfer of allodepleted donor T cells could enhance immune reconstitution by restoring the broad T cell repertoire and thus immunity to infectious pathogens without inducing GVHD. One strategy for allodepletion involves the removal of allo activated T cells on the basis of their expression of activa tionassociated cell surface markers, such as CD25, CD69, CD71 or CD134. Allodepletion is achieved by using anti bodies specific for these markers conjugated to toxins or micromagnetic beads (FIG. 2a) . Other strategies remove alloactivated T cells with chemotherapeutic drugs 53 or photodynamic purging
54
, or on the basis of proliferation 55 . Despite extensive in vitro studies, only a few clinical trials have been conducted with this approach. Their results, although encouraging with respect to improved immuno competence, clearly demonstrate that complete specific allodepletion has not been achieved, as GVHD is still a major problem [56] [57] [58] . There are several potential limita tions to these allodepletion strategies, including unsyn chronized expression of activation markers by alloreactive T cells, stimulation of only immuno dominant clones in alloreactivity assays (which means that lessdominant alloreactive T cells are not depleted), and failure of a single activation marker to identify all alloreactive T cells. The use of two activation markers may improve the efficacy of allodepletion 59 , and more potent stimulators may trigger increased expression of activation markers 60 , resulting in better allodepletion 55 .
Infusion of pathogen-specific T cells. Transfer of in vitro expanded pathogenspecific T cell clones can restore immunity to Epstein-Barr virus (EBV), cytomegalovi rus and adenovirus infections following HCT (FIG. 2b) . These virusspecific T cells can be selected by using antigenspecific tetramers 61 or streptamers 62 , or by iso lating interferonγ (IFNγ)secreting T cells in response to pathogenderived antigen stimulation 63 . The selected T cells are subsequently expanded in vitro. Infusion of these T cells can lead to successful disease control [62] [63] [64] . T cells specific for fungal pathogens, such as Aspergillus fumigatus, can also be expanded in vitro 65 . However, the efficacy of controlling fungal infections in HCT patients by this approach is currently unknown. The cumbersome isolation and expansion processes, which require special expertise, and the fact that immunity can only be restored to selected infectious agents currently limit the general applicability of the approach. However, it may be possible to broaden its utility, as effector populations have been successfully generated against multiple viruses for post transplant immunotherapy 65 . Thirdparty allogeneic r E V i E W S 408 | JUNE 2012 | VOLUME 12
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Suicide gene
A gene whose product can induce cell death by apoptosis.
Ganciclovir
An antiviral medication used to treat or prevent cytomegalovirus infections.
EBVspecific T cells have demonstrated efficacy in controlling EBVassociated malignancy 66, 67 , suggesting that this therapy could also be used when HCT donor derived T cells are not available, as in UCB transplanta tion. Infusion of the thirdparty allogeneic EBVspecific T cells was not associated with increased GVHD or toxic ity, but immune responses of the recipients to these cells may limit their survival. Despite the failure of these cells to induce the generation of alloantibodies 67 , they did not persist posttransfer, and multiple infusions were required for effective treatment, suggesting that these cells were eventually rejected by the recipients 66 .
Transplantation of expanded lymphoid progenitor cells.
A decreased number of lymphoid progenitor cells access ing the thymus can limit T cell reconstitution 68, 69 , and the addition of T cell progenitors to the donor graft has been shown to enhance immune reconstitution following experimental allogeneic HCT (FIG. 2c) . Two studies showed that immune reconstitution can be enhanced through the transfer of T cell precursors generated in vitro using stromal cells transduced with a NOTCH1 ligand or using immobilized NOTCH1 ligands 70, 71 . In addition to boost ing immune recovery, transplanting these T cell precur sors enhanced GVT effects without inducing GVHD 70, 72 . A recent study showed that cotransplantation of human in vitrogenerated T cell precursors with CD34 + cells to immunodeficient mice resulted in rapid appearance of new T cells in the lymphoid tissues, suggesting that this approach has considerable promise 73 .
Transfer of suicide gene-transduced donor T cells.
Several groups have investigated the use of suicide gene transduced donor T cells to enhance immune reconstitu tion while controlling GVHD (FIG. 2d) . The transgene ena bles the rapid killing of donor T cells when GVHD arises. In a nonrandomized Phase I/II clinical trial, herpes simplex thymidine kinase suicide genetransduced donor T cells were infused to recipients of haploidentical HCT following myeloablative conditioning 74 . Among patients who received transduced T cells, better immune reconsti tution and fewer infections were seen in those who showed engraftment of the transduced cells compared with patients who did not. In most patients who developed GVHD, administration of ganciclovir, which kills transgeneposi tive T cells, effectively controlled GVHD, although a short course of other immunosuppressants was also needed in some patients. Despite control of GVHD by ganciclovir administration, some transduced donor T cells survived and contributed to immune reconstitution. One interest ing finding in this study was that the administration of genetransduced donor T cells enhanced the reconstitu tion of nontransduced donorderived T cells, suggesting that the transduced T cells facilitated the expansion or the de novo generation of donor T cells.
Another study 75 tested this strategy using a differ ent gene construct for transduction of donor T cells. The construct fuses human caspase 9 to a modified human FK506binding protein, the dimerization of which in the presence of a synthetic dimerizing drug leads to the activation of caspase 9 and thus rapid death of cells expressing the construct. Donor T cells under went allodepletion by use of a CD25specific antibody conjugated with immunotoxin and were then trans duced with this construct. Selected transduced donor T cells were given to five patients receiving haploi dentical CD34 + cells after myeloablative conditioning. Four of these patients developed GVHD, which was promptly and effectively controlled by administration of the dimerizing drug AP1903 without the use of other immunosuppressants. AP1903 depleted >90% of trans duced donor T cells within 24 hours of injection. As in REF. 74 , AP1903 did not deplete all transduced donor T cells, as transgenepositive T cells could be detected again 1-2 weeks after apoptosis induction. More impor tantly, virusspecific donor T cells were at least to some degree preserved, perhaps explaining the absence of viral infections in the five patients despite the receipt of T cell depleted grafts. The authors considered that the apop tosisinducing agent might lead to the selective death of alloactivated T cells, as alloactivation could increase the expression of the suicide gene. Thus, a small number of unstimulated virusspecific T cells survived the apo ptosis induction and were sufficient to mediate effec tive antivirus immunity in these patients. Compared to the thymidine kinase suicide genebased approach, this caspase 9based approach induces faster death of the transduced T cells while sparing ganciclovir for use as an antiviral therapy. This construct is also less immuno genic. Collectively, infusion of suicide genetransduced donor T cells is a promising approach to enhancing immune reconstitution following HCT. However, more clinical studies are required to confirm its efficacy.
Use of biological agents. Several categories of exogenous factors have been shown to enhance immune reconstitu tion in animal models. These factors include cytokines (such as IL7), agents blocking sex hormones, and keratinocyte growth factor (KGF; also known as FGF7). They can improve immune reconstitution by enhancing the peripheral homeostatic proliferation and survival of mature T cells and/or thymopoiesis, which is reviewed in detail elsewhere 76, 77 . However, KGF did not show effi cacy in clinical trials 78 , despite hopes that it could improve thymic recovery. Encouraging results have been obtained from a smallscale clinical trial of the use of sex hormone blockade to enhance thymopoiesis 79 . Animal studies sug gest that KGF and sex hormone blockade may have syner gistic effects 80 , which needs to be further tested in clinical trials. Clinical trials to determine the effects of growth hormone, IL2 and IL7 on immune reconstitution in HCT patients are currently in progress 77 .
HCT as a tumour immunotherapy
A major mechanism by which HCT mediates GVT effects is via potent alloresponses mounted by hostreactive donor T cells recognizing alloantigens expressed on host cells, including the malignant cells (FIG. 3a) www.nature.com/reviews/immunol r E V i E W S Induction of tumour-specific immunity by alloresponses. Both GVH and hostversusgraft (HVG) alloresponses must be considered in HCT. These alloresponses are characterized by high frequencies of alloreactive T cells, which may produce an inflammatory environment that promotes concurrent immune responses against tumour associated antigens. Surprisingly, some clinical studies have demonstrated an association between rejection of donor bone marrow and the regression of advanced recipient haematological malignancies [81] [82] [83] [84] . These obser vations suggest that HVG alloresponses might trigger tumourspecific responses mediated by host immune cells, and this phenomenon has been demonstrated experimentally in an animal model [85] [86] [87] . As GVHD does not occur in patients [81] [82] [83] [84] or animals 85, 86 that lose chimer ism, the intentional rejection of engrafted donor bone marrow might provide an interesting strategy for sepa rating GVHD and GVT effects. Our studies in an ani mal model showed that HVG alloresponses leading to the rejection of engrafted donor bone marrow induce antitumour responses 85 , which are associated with the development of tumourspecific cellmediated cytotox icity 88 . Antitumour effects are dependent on IFNγ, which is mostly produced by CD8 + T cells 85, 89 , and on host invari ant NKT cells, which are not required as a source of IFNγ but which induce NK cell and dendritic cell activation 87 . These data collectively suggest that the HVG alloresponse mediating donor bone marrow rejection generates a pro inflammatory environment that in turn supports both adaptive immune responses against tumour antigens and innate immune responses mediated by NKT cells. The exact roles of NKT cells remain to be defined, but may include APC activation to promote tumour specific cytotoxic T lymphocyte activation and/or direct tumour cytotoxicity. Notably, the timing of NKT cell acti vation indicates that it is induced by the alloresponse, in contradistinction to the usual paradigm of innate immu nity promoting adaptive immunity. In this instance, an 'innate' NKT cell response is induced by an adaptive immune response, namely the alloresponse. A clinical trial is underway to test this strategy in patients (FIG. 3b) .
Experimental and clinical data indicate that GVH alloresponses can also potentiate GVT effects by facili tating the generation of tumour antigenspecific T cell responses. In a parenttoF1 HCT model, the develop ment of GVHD was associated with the generation of antitumour immunity against donorderived tumours. This indicates that donorderived alloreactive T cells support the development of donor T cellmediated anti tumour immune responses, rather than directly medi ating antitumour effects themselves 90 . Tumourspecific and nonalloreactive T cell clones recognizing a tumour derived antigen have been isolated from patients who responded to allogeneic HCT for the treatment of renal cell carcinoma, suggesting that tumourspecific T cells can mediate antitumour effects induced by allogeneic HCT 91 . Similar observations have been made in other studies 92, 93 . Further understanding of how alloresponses can facilitate the generation of tumourspecific T cells could help to enhance the GVT effects of HCT (FIG. 3a) , but the ability to separate this outcome from GVHD remains a challenge.
Potentiation of antitumour effects by induction of lymphopaenia. Autologous HCT has a role in strate gies used to amplify the antitumour effects induced by tumour vaccination 94 or adoptive immunotherapy 95, 96 in the absence of either GVH or HVG alloresponses. Multiple factors that potentiate tumourspecific T cell responses have been implicated. Conditioning by irra diation depletes T Reg cells that suppress antitumour T cell responses 95 . Lymphopaenia induced by condi tioning also increases the availability of homeostatic cytokines, such as IL7 and IL15, which enhance the responses of tumourspecific T cells 95 . Translocation of bacterial lipopolysaccharide (LPS), which is a potent Tolllike receptor 4 (TLR4) agonist and can trigger the production of multiple proinflammatory cytokines, including IL1, IL12 and type 1 IFNs, results from damage of the gastrointestinal tract by condition ing therapies. Microbial translocation enhances antitumour effects mediated by adoptive transfer of tumourspecific T cells and increases their expan sion 96 . Clinical studies demonstrate that increasing the intensity of conditioning increases the potency of adoptive cell therapy against metastatic melanoma 97, 98 ( FIG. 3c) . Autologous HCT is given in these cases for haematopoietic rescue.
Delayed donor leukocyte infusion to mixed chimaeras.
We have shown in animal models that potent GVT effects can be induced without GVHD by delayed administration of DLIs to established mixed chimae ras 99, 100 . The delay before DLI administration allows mixed chimerism to be achieved, and hence the donor specific tolerance that is needed to prevent rejection of the DLI, and provides time for the inflammation asso ciated with the original HCT conditioning to subside. GVHreactive donor T cells in the DLI are activated by recipient professional APCs present in mixed (but not fully allogeneic) chimaeras 99, 101 and mediate potent GVH alloresponses confined to the lymphohaemato poietic system. The lack of inflammation in the host environment markedly decreases the ability of activated, expanded GVHreactive T cells to infiltrate the epithe lial GVHD target tissues 101 . The GVH alloresponses convert mixed chimerism into full donor chimerism by eliminating all host haematopoietic cells, including the tumour cells, thus mediating GVT effects. Clinical stud ies translating this finding have demonstrated that GVT effects can be induced with a relatively low incidence and severity of GVHD, even in the HLAmismatched setting 49, 102 (FIG. 3d) . However, the clinical studies cited are aimed at avoiding T cell administration in the ini tial HCT inoculum, a component of the strategy that is likely to be important in avoiding an inflammatory state (due to GVH alloresponses in freshly conditioned hosts) before DLI.
Studies in the above animal model have revealed the importance of conditioninginduced inflammation in the pathogenesis of GVHD. Delayed DLI was capa ble of causing systemic or tissue GVHD when it was coadministered with a systemic or local TLR agonist, respectively 101 . These studies demonstrate the crucial part 
Haemoglobinopathies
Diseases caused by genetic defects that lead to one of the globin chains of the haemoglobin molecule developing an abnormal structure.
played by inflammation in attracting alloactivated donor T cells to infiltrate the GVHD target tissues, providing an explanation for the wellknown ability of bacterial LPS translocation to promote GVHD. Inflammation is associated with upregulated expression of chemokines and adhesion molecules that may be important in T cell adhesion and transmigration into epithelial tissues. Consistent with this notion, irradiation alone upregu lates the expression of multiple chemokines in these tissues, and their expression is further amplified by the GVH alloresponse 103 . Although delayed administration of a large number of donor T cells to quiescent mixed chimaeras induces GVT effects without GVHD, the mag nitude of the GVT effect was reduced compared to that in freshly conditioned hosts, showing that the inflammatory host environment helps to enhance GVT effects, but at the expense of markedly increased GVHD. Furthermore, activation of hostreactive donor CD8 + T cells was CD4
+ T H celldependent in delayed DLI recipients, but T H cellindependent in freshly conditioned hosts, and the effector functions of donor CD8 + T cells were impaired on a per cell basis in delayed DLI recipients. Effector function was restored by coadministration of a TLR agonist 104 . Moreover, exhaustion of hostreactive donor T cells occurs after mixed chimaeras receiving DLI convert to full donor chimerism owing to persistent stimulation by the host alloantigens expressed on the nonhaematopoietic tissues 105 , and this is associated with loss of antitumour effects over time 100 . In summary, alloresponses triggered by alloantigens can mediate GVT effects directly and can also promote the generation of tumourspecific T cell responses. More effort is needed to elucidate the mechanisms of these processes in order to potentiate the GVT effects while avoiding GVHD. Although autologous HCT itself does not mediate GVT effects, it enables the generation of a proinflammatory environment that can greatly potentiate the efficacy of tumourspecific T cells.
HCT for immune tolerance induction
To date, HCT has been mainly used for the treatment of haematological malignancies and genetic disorders of the haematopoietic system, such as immunodeficiency diseases and haemoglobinopathies. Recent research has extended the use of HCT to additional disease categories (TABLE 1) .
Allogeneic solid organ transplantation. Early murine studies demonstrated that induction of mixed haema topoietic chimerism using lethal irradiation as condi tioning could achieve longterm tolerance to allogeneic donor tissues. However, the toxicity of such condition ing regimens and the risk of GVHD that is associated with this approach is not acceptable for clinical organ transplantation. As nonmyeloablative conditioning regimens evolved, studies in large animals confirmed that bone marrow transplantation could promote longterm tolerance to kidney grafts from the same donor, even when mixed chimerism was only transient. Recently, two groups have reported successful combined bone marrow and kidney transplantation using two different conditioning regimens developed at MGH and Stanford University [106] [107] [108] (TABLE 2) . These patients were condi tioned by reducedintensity conditioning regimens fol lowed by transplantation of HLAmismatched (MGH) 106 or HLAmatched (MGH 109 and Stanford 107, 108 ) bone mar row cells and kidney grafts simultaneously from the same donor. Immunosuppression was discontinued around 9-12 months posttransplant. Some of these patients have been off immunosuppression for 2-13 years without evi dence of rejection 106, 109 . Persistent mixed chimerism was induced in the HLAidentical studies, whereas only tran sient mixed chimerism was seen in the HLAmismatched transplant study at MGH.
The mechanisms underlying the induction of tol erance to donor kidney grafts despite the transient nature of mixed chimerism are under active investiga tion. In mice, mixed chimerism induces the deletion of any donorreactive T cells that develop in the thymus, whereas the conditioning regimen depletes or tolerizes donorreactive T cells that preexist in the recipients 110 . However, in the nonhuman primate large animal model and HLAmismatched clinical trial, the initial T cell depletion of the host is less complete than in the mouse, and chimerism is only transient. Thus, it is likely that HCT with a kidney transplant induces toler ance of preexisting donorreactive mature T cells and that longterm tolerance is not due to lifelong intra thymic deletion. Specific unresponsiveness of T cells to donor alloantigens is seen in the combined transplant recipients. By contrast, patients who underwent alloge neic HCT for the treatment of haematological malig nancies but who did not receive a kidney transplant and also failed to achieve durable chimerism had T cell reactivity to donor antigens 111 . This finding suggests an active role for the kidney allograft itself in inducing or maintaining tolerance in the combined transplant patients 112 . Mechanistic studies suggest a role for host T Reg cells that are not fully depleted by the condition ing regimen. For the Stanford studies, NKT cells and T Reg cells have been implicated in suppressing rejection of the donor graft 113, 114 . Recently, five of eight patients receiving combined kidney and bone marrow transplantation from exten sively HLAmismatched, related or unrelated donors after conditioning with the Johns Hopkins regimen (which involves pre and posttransplant cyclophospha mide treatment, plus fludarabine and lowdose TBI) were reported to develop full chimerism without GVHD and to accept donor kidneys for up to 1 year after the removal of all immunosuppression 115 . The patients received donor T cells in the peripheral blood stem cell grafts that they were given, and the absence of GVHD was attributed by the authors to the coinfusion of 'facilitating cells' , a cell type previously described by this group in mouse models 116 . The lineage origin of these cells is somewhat unclear, and the proprietary nature of the method for their isolation has precluded wider assessment of their utility. One patient in the small study suffered a near lethal infectious complication, and there is reason to be concerned about immunocompetence in full allogeneic chimaeras with peripheral APCs that are extensively HLAmismatched from the recipient's thymus if T cell 
Natural antibody
Antibodies that are detected in the sera of normal individuals without any previous sensitization to the antigen. They can bind pathogens and self-antigens, such as ABO blood-group antigens.
reconstitution occurs there. T cell counts remained low for the duration of the followup study, and it is possible that these cells were derived from the expansion of pre existing T cells in the graft. Thus, the potential of this method to safely induce allograft tolerance is unclear.
Xenogeneic transplantation. Xenotransplantation is a potential solution for the shortage of organs in clinical transplantation, but B cellmediated humoral responses and T cellmediated responses both present major bar riers (reviewed in REF. 117 ). Natural antibodies directed against Galα13Galβ14GlcNAc (α1,3Gal) expressed on xenografts, the synthesis of which depends on the enzyme α1,3galactosyltransferase (αGalT), cause hyper acute rejection of xenografts to humans or Old World primates. It has been shown in GalTknockout mice (which, like humans, produce α1,3Galspecific antibod ies) that induction of mixed chimerism by xenogeneic HCT tolerizes T cells and natural antibodyproducing B cells, so that xenogeneic rat heart grafts survive in the long term without immunosuppression 118 . Whereas T cell tolerance to the xenogeneic antigens may solely depend on thymusmediated deletion of xenoreactive T cells, tolerization of antiGalproducing cells involves an early anergy mechanism and clonal deletion and/or receptor editing mechanism at a later phase 119 . Moreover, NK cell tolerance to xenogeneic cells is also induced by mixed chimerism, which is characterized by global unresponsiveness of NK cells in mixed xenogeneic chi maeras 120 . The induction of NK cell tolerance may be due to the high level of stimulation without inhibitory signals from the xenogeneic cells during NK cell devel opment, as xenogeneic ligands generally trigger activat ing but not inhibitory signals in NK cells. Recent studies in a swinetobaboon model show that engraftment of GalTknockout swine bone marrow cells was associated with B cell hyporesponsiveness to donor xeno antigens 121 . Thus, induction of mixed xenogeneic chimerism is an important strategy for induction of tolerance to xenografts and warrants further investigation. Treatment of autoimmune diseases. Clinical data obtained over the past 15 years show that autologous HCT can be effective against severe and therapyrefrac tory autoimmune diseases, including Crohn's disease, sys temic sclerosis, systemic lupus erythematosus, multiple sclerosis and juvenile idiopathic arthritis 122, 123 . Although autologous HCT can generally induce regression of these autoimmune diseases, relapse frequently occurs at later time points, indicating that tolerance to autoantigens has not been totally restored. Another issue is that treat ment of autoimmune diseases with HCT can later give rise to secondary autoimmune diseases 124 . Identification of the patient groups most likely to benefit from HCT is an important challenge in each disease. The mecha nisms by which autologous HCT corrects autoimmune diseases are unclear. Both clinical 125 and experimental HCT that may have promoted tolerance through trans forming growth factorβ (TGFβ) production 127 . The depletion of preexisting autoreactive lymphocytes by the conditioning therapy before HCT might be an impor tant mechanism of disease regression, especially when purified CD34 + cells are given back. HCT can then be associated with the generation of a new T cell pool that may be tolerant to selfantigens 128 . Aside from autologous HCT, allogeneic HCT has been found to mediate a graftversusautoimmunity effect, which, like GVT effects, is associated with GVHD. Although performed much less frequently than auto logous HCT for the treatment of autoimmune diseases, allogeneic HCT has been associated with regression of multiple refractory autoimmune diseases 129 . Although GVH responses that eliminate all host haematopoietic cells, including autoreactive T and B cells, are thought to be the main mechanism for this therapeutic effect, intentional induction of mixed haematopoietic allo geneic chimerism has also been shown to reverse or attenuate autoimmune diseases in multiple animal models, including type 1 diabetes, systemic lupus erythe matosus and arthritis models [130] [131] [132] [133] [134] [135] . Induction of mixed chimerism through allogeneic HCT leads to tolerance of autoreactive T cells and B cells [130] [131] [132] [133] [134] [135] . In line with these experimental data, there are case reports of successful treatment of patients with various autoimmune diseases by nonmyeloablative allogeneic HCT [136] [137] [138] [139] . However, clinical trials testing this approach are not yet underway.
Multiple mechanisms may be involved in restoring tolerance to autoantigens by mixed chimerism induc tion. Although deletion of autoreactive T cells in the thymus postHCT has been shown in an animal model in which peripheral T cells were removed with a T cell depleting antibody during conditioning for HCT 133 , other mechanisms must be invoked to explain the toleri zation of peripheral autoreactive T cells that persist fol lowing some nonmyeloablative conditioning protocols, such as one used in nonobese diabetic (NOD) mice with advanced type 1 diabetes 132 . Possible mechanisms include anergy or deletion of peripheral autoreactive T cells, or T Reg cellmediated regulation 140 . Preliminary data support a T Reg mediated mechanism.
In conclusion, HCT is a powerful tool for inducing tolerance to a wide range of antigens, including xeno antigens and autoantigens. More studies are required to elucidate the mechanism of tolerance to these antigens that is induced by HCT.
Future perspectives
HCT is a fastevolving cellular therapy. Substantial pro gress has been made in the field, including new applica tions and improved outcomes. Increased safety of this therapy and the use of alternative donors will enable its wider clinical use beyond the treatment of malignant diseases. Although preventing GVHD while preserv ing GVT effects and improving immune reconstitution posttransplant are still the most challenging issues, recent advances have led to an improved understand ing of GVHD and the suggestion of novel strategies to overcome these hurdles.
